GLYCOSCOREDX LIMITED
Company number 12766216 · Monitor this company
Executive summary
GlycoScoreDX Limited is a small, development-stage biotech company with positive net current assets but showing accumulated losses and going concern uncertainties. Liquidity remains adequate for now, supported by cash reserves, but ongoing cash burn and increased creditors warrant cautious credit support. Conditional approval is recommended with close monitoring of cash flow, trade payables, and operational progress.
Shareholders' funds
£747,122
Balance sheet as at 2024-07-31
Overview
- Company type
- Private Limited Company
- Incorporated
- 2020-07-24
- Dissolved
- 2026-05-12
- Registered office
- Sandgate House, 102 Quayside, Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NE1 3DX
- Postcode
- NE1 3DX
- Capital
- 13 GBP
- Accounts category
- Total Exemption Full
Accounts
- Last made up to
- 2024-07-31
- Financial year end
- 31 July
Confirmation statement
- Last statement dated
- 2025-07-23
Nature of business (SIC)
- 20590 Manufacture of other chemical products not elsewhere classified
- 46180 Agents specialized in the sale of other particular products
- 72110 Research and experimental development on biotechnology
- 86900 Other human health activities
Officers 3 current · 2 resigned
Group structure
Controlled by INNOVATION GP LIMITED — since 2023-06-02
From persons-with-significant-control filings on the public register.
Contact details
- Website
- glycoscoredx.co.uk
Introducing the GlycoScore Prostate Cancer Test, a simpleblood test enabling accurate early detection of aggressiveprostate cancer
The class of 2020
32%
of the 775,720 companies incorporated in 2020 are still active today; 64% have since been dissolved.
A fact about the year, not a forecast for this company.